MRK - Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment | Benzinga
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.
The study saw a combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
The results are being presented today at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
The preliminary analysis of the ...